Latest News about NVS
Recent news which mentions NVS
Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD
March 25, 2022
Tickers
NVS
From Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
March 24, 2022
From Motley Fool
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
March 24, 2022
From Benzinga
FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer
March 24, 2022
Tickers
NVS
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
This group of stocks is flagging a rebound, and that’s good news for the S&P 500, says technical analyst
March 22, 2022
From MarketWatch
From Motley Fool
2 Top Stocks to Buy in March and Hold Forever
March 15, 2022
From Motley Fool
Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study
March 14, 2022
Tickers
NVS
From Benzinga
From Benzinga
From Benzinga
3 No-Brainer Stocks to Buy With $1,000 Right Now
March 14, 2022
From Motley Fool
From Benzinga
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
March 10, 2022
Tickers
NVS
From Benzinga
7 Drug Stocks To Consider After the Viatris Plunge
March 10, 2022
From InvestorPlace
From Benzinga
Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
March 08, 2022
From Benzinga
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
March 07, 2022
From Benzinga
Viatris Just Snagged a Major FDA Approval
March 03, 2022
From Motley Fool
Consumer Spending, E-Commerce, and the Business of Lodging
March 02, 2022
From Motley Fool
From Benzinga
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
February 23, 2022
From Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
From Benzinga
New FDA program could boost drug development for rare diseases
February 15, 2022
From MarketWatch
3 High-Yield Dividend Stocks to Buy and Hold for Decades
February 12, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.